Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

Viatris' improving sales trends and margins combined with meaningful development opportunities could help boost its valuation multiple. Viatris combines stable cash flow from established drugs with a ...

A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...

The compiler infers, but does not take instructions. There is no syntax for explicit type declarations yet, and the new type ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

HT SyndicationNew Delhi [India], June 15: A study conducted by FindMyCollege, covering more than 1 lakh active IT jobs in the current market, finds the pay ladder starting at a median of ₹2.6 LPA ...

US Supreme Court Backs Generic Drugmaker in 'Skinny Label' Patent Case By Blake Brittain WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication ...

Drugmaker Hikma’s generic version of Irish-American company Amarin Pharma’s cardiovascular medication Vascepa did not infringe ‌Amarin’s patents, the US supreme court ruled on Thursday in a decision ...

Four decades ago, Canadian endocrinologist Dr. Daniel Drucker’s breakthrough discoveries led to the creation of semaglutide, the active ingredient in drugs like Ozempic and Wegovy — and forever ...